Biotech firm signs $700M schizophrenia drug deal with Merck

01/3/2008 | Reuters

Addex Pharmaceuticals SA today announced it is collaborating with U.S.-based Merck & Co. to develop ADX63365, Addex's drug for schizophrenia. The deal grants the Swiss biotech firm $22 million upfront and makes it eligible for up to $680 million in milestone payments.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations